Peptides DB
Research-centric peptide and protocol reference hub
NatureNovember 9, 2026Trial readout

Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial

Reported by Nature. Read the original →

What the story says

The headline reports on a randomized controlled trial investigating the effects of resistance exercise on lean mass loss during tirzepatide therapy for obesity. The study aims to assess whether incorporating resistance exercise can mitigate the loss of lean mass associated with this treatment.

Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • Tirzepatide has 33 studies on file, 19 of them in humans, the newest published 2026.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.